Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications

American Journal of Medicine

Volumn 124, Issue 1 SUPPL., 2011, Pages S3-

  Nauck, Michael A ^a  

^a Bad Lauterberg Diabetes Center   (Germany)

Author keywords

Cardiovascular; Dipeptidyl peptidase4 inhibitor; Glucagonlike peptide1 receptor agonist; Incretin based therapies; Type 2 diabetes mellitus; Cell

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 AGONIST; GLUCOSE; INCRETIN; LIRAGLUTIDE; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ACUTE HEMORRHAGIC PANCREATITIS; ARTICLE; BRONCHITIS; CARDIOVASCULAR FUNCTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 78650753885     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2010.11.002     Document Type: Article

References (189)

1. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
2. T. Vilsbøll, and J.J. Holst Incretins, insulin secretion and Type 2 diabetes mellitus Diabetologia 47 2004 357 366
3. J.J. Holst Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential Trends Endocrinol Metab 10 1999 229 235
4. C.F. Deacon What do we know about the secretion and degradation of incretin hormones? Regul Pept 128 2005 117 124
5. H.C. Fehmann, R. Gke, and B. Gke Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide Endocr Rev 16 1995 390 410
6. A.M. Buchan, J.M. Polak, C. Capella, E. Solcia, and A.G. Pearse Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man Histochemistry 56 1978 37 44
7. R. Eissele, Gke R, and S. Willemer Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man Eur J Clin Invest 22 1992 283 291
8. C. Ørskov, L. Rabenhøj, A. Wettergren, H. Kofod, and J.J. Holst Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans Diabetes 43 1994 535 539
9. B. Kreymann, M.A. Ghatei, G. Williams, and S.R. Bloom Glucagon-like peptide-1 736: a physiological incretin in man Lancet 2 1987 1300 1304
10. I.G. Cleator, and R.H. Gourlay Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances Am J Surg 130 1975 128 135
11. J.J. Meier The contribution of incretin hormones to the pathogenesis of type 2 diabetes Best Pract Res Clin Endocrinol Metab 23 2009 433 441
12. L. Hansen, S. Lampert, H. Mineo, and J.J. Holst Neural regulation of glucagon-like peptide-1 secretion of pigs Am J Physiol Endocrinol Metab. 287 2004 E939 E947
13. C. Herrmann, R. Gke, G. Richter, H.C. Fehmann, R. Arnold, and B. Gke Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients Digestion 56 1995 117 126
14. C. Qualmann, M.A. Nauck, J.J. Holst, C. Ørskov, and W. Creutzfeldt Glucagon-like peptide 1 (736 amide) secretion in response to luminal sucrose from the upper and lower gut: a study using α-glucosidase inhibition (acarbose) Scand J Gastroenterol 30 1995 892 896
15. H.J. Jang, Z. Kokrashvili, and M.J. Theodorakis Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1 Proc Natl Acad Sci U S A 104 2007 15069 15074
16. M. Nauck, F. Stckmann, R. Ebert, and W. Creutzfeldt Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes Diabetologia 29 1986 46 52
17. N. McIntyre, C.D. Holdsworth, and D.S. Turner Intestinal factors in the control of insulin secretion J Clin Endocrinol Metab 25 1965 1317 1324
18. H. Elrick, L. Stimmler, C.J. Hlad Jr, and Y. Arai Plasma insulin response to oral and intravenous glucose administration J Clin Endocrinol Metab 24 1964 1076 1082
19. M.A. Nauck, E. Homberger, and E.G. Siegel Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses J Clin Endocrinol Metab 63 1986 492 498
20. C. Ørskov, A. Wettergren, and J.J. Holst Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day Scand J Gastroenterol 31 1996 665 670
21. M.A. Nauck, E. Bartels, C. Ørskov, R. Ebert, and W. Creutzfeldt Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near physiological insulinotropic hormone and glucose concentrations J Clin Endocrinol Metab 76 1993 912 917
22. J.J. Holst, and J. Gromada Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans Am J Physiol Endocrinol Metab 287 2004 E199 E206
23. B. Tronier, A. Dejgaard, T. Andersen, and S. Madsbad Absence of incretin effect in obese type 2 and diminished effect in lean type 2 and obese subjects Diabetes Res Clin Pract suppl 1 1985 S586
24. M.B. Toft-Nielsen, M.B. Damholt, and S. Madsbad Determinants of the impaired secretion of glucagon-like peptide1 in type 2 diabetic patients J Clin Endocrinol Metab 86 2001 3717 3723
25. T. Vilsbøll, T. Krarup, C.F. Deacon, S. Madsbad, and J.J. Holst Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients Diabetes 50 2001 609 613
26. E. Muscelli, A. Mari, and A. Casolaro Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients Diabetes 57 2008 1340 1348
27. J.J. Meier, and M.A. Nauck Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab 4 2008 606 607
28. K. Vollmer, J.J. Holst, and B. Baller Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance Diabetes 57 2008 678 687
29. C. Ørskov, J. Jeppesen, S. Madsbad, and J.J. Holst Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine J Clin Invest 87 1991 415 423
30. I.R. Jones, D.R. Owens, S. Luzio, S. Williams, and T.M. Hayes The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus Diabetologia 32 1989 668 677
31. S.A. Ross, J.C. Brown, and J. Dupr Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus Diabetes 26 1977 525 529
32. W. Kim, and J.M. Egan The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 60 2008 470 512
33. M.A. Nauck, M.M. Heimesaat, C. Ørskov, J.J. Holst, R. Ebert, and W. Creutzfeldt Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J Clin Invest 91 1993 301 307
34. M.A. Nauck, B. Baller, and J.J. Meier Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes Diabetes 53 suppl 3 2004 S190 S196
35. M. Nauck Glucagon-like peptide-1 in type-2 diabetes: the β-cell and beyond Diabetes Obes Metab 10 2008 2 13
36. J.J. Meier, K. Hcking, J.J. Holst, C.F. Deacon, W.H. Schmiegel, and M.A. Nauck Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes Diabetes 50 2001 2497 2504
37. T. Vilsbøll, T. Krarup, S. Madsbad, and J.J. Holst Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients Diabetologia 45 2002 1111 1119
38. G. Xu, H. Kaneto, and D.R. Laybutt Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes Diabetes 56 2007 1551 1558
39. J.J. Holst, J. Gromada, and M.A. Nauck The pathogenesis of NIDDM involves a defective expression of the GIP receptor Diabetologia 40 1997 984 986
40. A. Kubota, Y. Yamada, and T. Hayami Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDMno evidence of association with Japanese NIDDM subjects Diabetes 45 1996 1701 1705
41. J.P. Fortin, J.C. Schroeder, Y. Zhu, M. Beinborn, and A.S. Kopin Pharmacological characterization of human incretin receptor missense variants J Pharmacol Exp Ther 332 2010 274 280
42. C. Ørskov, S.A. Hjorth, A.D. Jensen, and T. Vilsbøll Typical Danish Caucasian type 2 diabetic patients do not commonly carry genetic variants in GIP and GLP-1 encoding regions of the proGIP and proglucagon genes Regul Pept 119 2004 151 154
43. J.J. Meier, B. Gallwitz, and B. Kask Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects Diabetes 53 suppl 3 2004 S220 S224
44. C.W. Chia, O.D. Carlson, and W. Kim Exogenous glucose-dependent insulinotropic polypeptide worsens postprandial hyperglycemia in type 2 diabetes Diabetes 58 2009 1342 1349
45. M.A. Nauck, W.E. Schmidt, and J.J. Meier The incretin modulatorsincretin mimetics (GLP-1 receptor agonists) and incretin enhancers (DPP-4 inhibitors) C.E. Mogensen, Pharmacotherapy of Diabetes: New Developments Improving Life and Prognosis for Diabetic Patients. 2007 Springer United States: New York, NY 111 141
46. M.A. Nauck, M.M. Heimesaat, and K. Behle Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers J Clin Endocrinol Metab 87 2002 1239 1246
47. M. Zander, S. Madsbad, J.L. Madsen, and J.J. Holst Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study Lancet 359 2002 824 830
48. M.A. Nauck, I. Weber, and I. Bach Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients Diabet Med 15 1998 937 945
49. J. Rachman, B.A. Barrow, J.C. Levy, and R.C. Turner Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM Diabetologia 40 1997 205 211
50. S. Meier, K. Hcking, and R. Ritzel Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers Horm Metab Res 35 2003 551 556
51. S. Quddusi, T.P. Vahl, K. Hanson, R.L. Prigeon, and D.A. D'Alessio Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans Diabetes Care 26 2003 791 798
52. J.J. Meier, and M.A. Nauck Incretins and the development of type 2 diabetes Curr Diab Rep 6 2006 194 201
53. E.P. Kwan, and H.Y. Gaisano Glucagon-like peptide 1 regulates sequential and compound exocytosis in pancreatic islet β-cells Diabetes 54 2005 2734 2743
54. I.V. Holz GG, W.M. Khtreiber, and J.F. Habener Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) Nature 361 1993 362 365
55. J.J. Meier, and M.A. Nauck Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired β-cell function? Diabetes 59 2010 1117 1125
56. M.A. Nauck Unraveling the science of incretin biology Am J Med 122 suppl 2009 S3 S10
57. M.A. Nauck, and J.J. Meier Glucagon-like peptide 1 and its derivatives in the treatment of diabetes Regul Pept 128 2005 135 148
58. K.J. Hare, T. Vilsbøll, M. Asmar, C.F. Deacon, F.K. Knop, and J.J. Holst The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action Diabetes 59 2010 1765 1770
59. M. Salehi, B. Aulinger, R.L. Prigeon, and D.A. D'Alessio Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes Diabetes 59 2010 1330 1337
60. M.A. Nauck, N. Kleine, C. Ørskov, J.J. Holst, B. Willms, and W. Creutzfeldt Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (736 amide) in Type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 1993 741 744 (Pubitemid 23218642)
61. M.A. Nauck, A. Sauerwald, R. Ritzel, J.J. Holst, and W. Schmiegel Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure Diabetes Care 21 1998 1925 1931
62. L. Farilla, A. Bulotta, and B. Hirshberg Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets Endocrinology 144 2003 5149 5158
63. J. Buteau, W. El-Assaad, C.J. Rhodes, L. Rosenberg, E. Joly, and M. Prentki Glucagon-like peptide-1 prevents beta cell glucolipotoxicity Diabetologia 47 2004 806 815
64. P.L. Brubaker, and D.J. Drucker Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system Endocrinology 145 2004 2653 2659
65. D.A. Stoffers, T.J. Kieffer, and M.A. Hussain Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas Diabetes 49 2000 741 748
66. A. Bulotta, H. Hui, and E. Anastasi Cultured pancreatic ductal cells undergo cell cycle re-distribution and β-cell-like differentiation in response to glucagon-like peptide1 J Mol Endocrinol 29 2002 347 360
67. A. Flint, A. Raben, A.K. Ersbøll, J.J. Holst, and A. Astrup The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity Int J Obes 25 2001 781 792
68. C. Verdich, A. Flint, and J.P. Gutzwiller A meta-analysis of the effect of glucagon-like peptide-1 (736) amide on ad libitum energy intake in humans J Clin Endocrinol Metab 86 2001 4382 4389
69. J.P. Gutzwiller, J. Drewe, and B. Gke Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2 Am J Physiol Regul Integr Comp Physiol 276 pt 2 1999 R1541 R1544
70. J.P. Gutzwiller, B. Gke, and J. Drewe Glucagon-like peptide-1: a potent regulator of food intake in humans Gut. 44 1999 81 86
71. A. Flint, A. Raben, A. Astrup, and J.J. Holst Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans J Clin Invest 101 1998 515 520
72. B. Willms, J. Werner, J.J. Holst, C. Ørskov, W. Creutzfeldt, and M.A. Nauck Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(736) amide in type 2 (noninsulin-dependent) diabetic patients J Clin Endocrinol Metab 81 1996 327 332
73. E. Nslund, N. King, and S. Mansten Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects Br J Nutr 91 2004 439 446
74. J. Schirra, M. Nicolaus, and R. Roggel Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans Gut 55 2006 243 251
75. C. Ørskov, J.J. Holst, and O.V. Nielsen Effect of truncated glucagon-like peptide-1 [proglucagon-(78107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach Endocrinology 123 1988 2009 2013
76. 2+ channel-dependent exocytosis Cell Metab 11 2010 543 553
77. J. Schirra, K. Sturm, P. Leicht, R. Arnold, B. Gke, and M. Katschinski Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-26)amide in humans J Clin Invest 101 1998 1421 1430
78. M. Salehi, T.P. Vahl, and D.A. D'Alessio Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion J Clin Endocrinol Metab 93 2008 4909 4916
79. L.A. Nikolaidis, S. Mankad, and G.G. Sokos Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 2004 962 965
80. G.G. Sokos, H. Bolukoglu, and J. German Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting Am J Cardiol 100 2007 824 829
81. G.G. Sokos, L.A. Nikolaidis, S. Mankad, D. Elahi, and R.P. Shannon Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure J Card Fail 12 2006 694 699
82. T. Nystrom, M.K. Gutniak, and A. Zhang Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease Am J Physiol Endocrinol Metab 287 2004 E1209 E1215
83. R. Chilton, J. Wyatt, S. Nandish, R. Oliveros, and M. Lujan Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of the glucagonlike peptide1-based therapies Am J Med 2010 xx:xxx-xxx [this supplement]
84. M.B. Toft-Nielsen, S. Madsbad, and J.J. Holst Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients Diabetes Care 22 1999 1137 1143
85. J.P. Gutzwiller, S. Tschopp, and A. Bock Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men J Clin Endocrinol Metab 89 2004 3055 3061
86. X. Qin, H. Shen, and M. Liu GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats Am J Physiol Gastrointest Liver Physiol 288 2005 G943 G949
87. J.J. Meier, A. Gethman, and O. Gtze Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans Diabetologia 49 2006 452 458
88. J.J. Holst, and C. Ørskov The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism Diabetes 53 suppl 3 2004 S197 S204
89. A.M. Lambeir, C. Durinx, S. Scharp, and I. De Meester Dipeptidyl peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV Crit Rev Clin Lab Sci 40 2003 209 294
90. C.F. Deacon, M.A. Nauck, J. Meier, K. Hking, and J.J. Holst Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide J Clin Endocrinol Metab 85 2000 3575 3581
91. T.J. Kieffer, C.H. McIntosh, and R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 1995 3585 3596
92. S.H. Havale, and M. Pal Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes Bioorg Med Chem 17 2009 1783 1802
93. B.D. Green, P.R. Flatt, and C.J. Bailey Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes Diab Vasc Dis Res 3 2006 159 165
94. C.H. McIntosh, H.U. Demuth, J.A. Pospisili, and R. Pederson Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept 128 2005 159 165
95. R. Mentlein, B. Gallwitz, and W.E. Schmidt Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(736) amide, peptide histidine methionine and is responsible for their degradation in human serum Eur J Biochem 214 1993 829 835
96. M. Hildebrant, W. Reutter, P. Arck, M. Rose, and B.F. Klapp A guardian angel: the involvement of dipeptidyl peptidase IV in physiconeuroendocrine function, nutrition and immune defence Clin Sci (Lond) 99 2000 93 104
97. D.J. Drucker Enhancing incretin action for the treatment of type 2 diabetes Diabetes Care 26 2003 2929 2940
98. A. Bergmann, and C. Bohuon Decrease of serum dipeptidylpeptidase activity in severe sepsis patients: relationship to procalcitonin Clin Chim Acta 321 2002 123 126
99. B. Richter, E. Bandeira-Echtler, K. Bergerhoff, and C. Lerch Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus Cochrane Database Sys Rev 2 2008 CD006739
100. E. Grouzmann, M. Monod, and B. Landis Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa FASEB J 16 2002 1132 1134
101. M. Zubrzycka, and A. Janecka Substance P: transmitter of nociception [minireview] Endocr Regul 34 2000 195 201
102. T. Oravecz, M. Pall, and G. Roderiquez Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)mediated cleavage J Exp Med 186 1997 1865 1872
103. G.R. Flentke, E. Munoz, B.T. Huber, A.G. Plaut, C.A. Ketttner, and W.W. Bachovchin Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function Proc Natl Acad Sci U S A 88 1991 1556 1559
104. E. Schn, S. Jahn, and S.T. Kiessig The role of dipeptidyl peptidase IV in human T lymphocyte activation: inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro Eur J Immunol 17 1987 1821 1826
105. B.D. Green, P.R. Flatt, and C.J. Bailey Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes Expert Opin Emerg Drugs 11 2006 525 539
106. K. Kos, A.R. Baker, and M. Jernas DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue Diabetes Obes Metab 11 2009 285 292
107. C.F. Deacon, and J.J. Holst Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes Expert Opin Investig Drugs 19 2010 133 140
108. 14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans Drug Metab Dispos 37 2009 536 544
109. R.E. Amori, J. Lau, and A.J. Pittas Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 298 2007 194 206
110. D. Williams-Herman, S.S. Engel, and E. Round Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes BMC Endocr Disord 10 2010 7
111. A. El-Ouaghlidi, E. Rehring, and J.J. Holst The didpeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion J Clin Endocrinol Metab 92 2007 4165 4171
112. C.F. Deacon, S. Wamberg, P. Bie, T.E. Hughes, and J.J. Holst Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs J Endocrinol 172 2002 355 362
113. R.A. DeFronzo, T. Okerson, P. Viswanathan, X. Guan, J.H. Holcombe, and L. MacConell Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study Curr Med Res Opin 24 2008 2943 2952
114. G.A. Herman, C. Stevens, and K. Van Dyck Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses Clin Pharmacol Ther 78 2005 675 688
115. M.O. Larsen, B. Rolin, and U. Ribel Valine pyrrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced β-cell mass Exp Diabesity Res 4 2003 93 105
116. M.K. Reimer, J.J. Holst, and B. Ahrn Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice Eur J Endocrinol 146 2002 717 727
117. M.A. Nauck, and A. El-Ouaghlidi The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1 Diabetologia. 48 2005 608 611
118. R. Burcelin, A. Da Costa, D. Drucker, and B. Thorens Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor Diabetes 50 2001 1720 1728
119. L. Hansen, C.F. Deacon, C. Ørskov, and J.J. Holst Glucagon-like peptide-1-(736) amide is transformed to glucagon-like peptide-1-(936) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine Endocrinology 140 1999 5356 5363
120. A. Mari, W.M. Sallas, and Y.L. He Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes J Clin Endocrinol Metab 90 2005 4888 4894
121. K.B. Degn, C.B. Juhl, and J. Sturis One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes Diabetes 53 2004 1187 1194
122. B. Ahren, and T.E. Hughes Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice Endocrinology 146 2005 2055 2059
123. N.M. Sherwood, S.L. Krueckl, and J.E. McRory The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily Endocr Rev 21 2000 619 670
124. D. Kim, L. Wang, and M. Beconi (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J Med Chem 48 2005 141 151
125. Januvia [prescribing information] 2010 Merck & Co., Inc Whitehouse Station, NJ
126. D.J. Augeri, J.A. Robl, and D.A. Betebenner Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J Med Chem 48 2005 5025 5037
127. Onglyza [prescribing information] 2009 Bristol-Myers Squibb Princeton, NJ
128. Galvus [summary of product characteristics] 2007 Novartis Europharm Limited Horsham, UK
129. Galvus' EU launch held up by safety update to physician labeling FDAnews Drug Daily Bulletin http://www.fdanews.com/newsletter/article?articleId= 100835&issueId=10975 November 9, 2007 Accessed August 25, 2010
130. US Securities & Exchange Commission Form 20-F 2009 [annual report] Basel, Switzerland: Novartis AG Filed January 26, 2010 http://ir2.flife.de/data/ novartis2009/igb-html/pdf/Novartis-20-F.PDF Accessed August 26, 2010.
131. J. Eng, W.A. Kleinman, L. Singh, G. Singh, and J.P. Raufman Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: further evidence for an exendin receptor on dispersed acini from guinea pig pancreas J Biol Chem 267 1992 7402 7405
132. Byetta [package insert] 2009 Eli Lilly and Company Indianapolis, IN
133. L.B. Knudsen, P.F. Nielsen, and P.O. Huusfeldt Potent derivatives of glucagon-like peptide1 with pharmacokinetic properties suitable for once daily administration J Med Chem 43 2000 1664 1669
134. I. Bjornsdottir, A. Olsen, and U. Larsen Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase Diabetologia 51 suppl 1 2008 S356 EASD abstract 891
135. Steensgaard DB, Thomsen JK, Olsen HB, Knudsen LB. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide. Presented at the 68th Annual Scientific Sessions of the American Diabetes Association (ADA); June 610, 2008; San Francisco, California. Abstract 552-P.
136. D.J. Drucker, J.B. Buse, K. Taylor DURATION-1 Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250
137. T.J. Moretto, D.R. Milton, and T.D. Ridge Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drugnaive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 30 2008 1448 1460
138. B. Zinman, B.J. Hoogwerf, and S. Durn Garcia The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial Ann Intern Med 146 2007 477 485
139. R.A. DeFronzo, R.E. Ratner, J. Han, D.D. Kim, M.S. Fineman, and A.D. Baron Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 28 2005 1092 1100
140. D.M. Kendall, M.C. Riddle, and J. Rosenstock Effects of exenatide (exendin-4) glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 28 2005 1083 1091
141. J.B. Buse, R.R. Henry, J. Han, D.D. Kim, M.S. Fineman, A.D. Baron Exenatide-113 Clinical Study Group Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 27 2004 2628 2635
142. J.B. Buse, D.C. Klonof, and L.N. Nielsenf Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials Clin Ther 29 2007 139 153
143. S. Bregenholt, A. Møldrup, and N. Blume The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro Biochem Biophys Res Commun 330 2005 577 584
144. J. Chen, F.M. Couto, A.H. Minn, and A. Shalev Exenatide inhibits β-cell apoptosis by decreasing thioredoxin-interacting protein Biochem Biophys Res Commun 346 2006 1067 1074
145. B.R. Gedulin, S.E. Nikoulina, and P.A. Smith Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight Endocrinology 146 2005 2069 2076
146. J. Sturis, C.F. Gotfredsen, and J. Rømer GLP-1 derivative liraglutide in rats with β-cell deficiencies: influence of metabolic state on β-cell mass dynamics Br J Pharmacol 140 2003 123 132
147. M.P. Gilbert, and R.E. Pratley Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus Am J Med 122 suppl 2009 S11 S24
148. A. Garber, R. Henry, and R. Ratner Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 2009 473 481
149. M. Marre, M. Brndle, W.M. Bebakar LEAD-1 SU study group Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Diabet Med 26 2009 268 278
150. M. Nauck, A. Frid, K. Hermansen LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study Diabetes Care 32 2009 84 90
151. D. Russell-Jones, A. Vaag, O. Schmitz Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial Diabetologia 52 2009 2046 2055
152. B. Zinman, J. Gerich, J.B. Buse LEAD-4 Study Investigators Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD) Diabetes Care 32 2009 1224 1230
153. J.B. Buse, J. Rosenstock, G. Sesti LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 2009 39 47
154. J.B. Buse, G. Sesti, W.E. Schmidt Liraglutide Effect and Action in Diabetes (LEAD)-6 Study Group Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents Diabetes Care 33 2010 1300 1303
155. T. Vilsbøll, B. Brock, and H. Perrild Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus Diabet Med 25 2008 152 156
156. I. Raz, Y. Chen, and M. Wu Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes Curr Med Res Opin 24 2008 537 550
157. K. Hermansen, M. Kipnes, E. Luo, D. Fanurik, H. Khatami, P. Stein Sitagliptin Study 035 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin Diabetes Obes Metab 9 2007 733 745
158. M.A. Nauck, G. Meininger, D. Sheng, L. Terranella, P.P. Stein Sitagliptin Study 024 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial Diabetes Obes Metab 9 2007 194 205
159. P. Aschner, M.S. Kipnes, J.K. Lunceford, M. Sanchez, C. Mickel, D.E. Williams-Herman Sitagliptin Study 021 Group Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 29 2006 2632 2637
160. B. Charbonnel, A. Karasik, J. Liu, M. Wu, G. Meininger Sitagliptin Study 020 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care 29 2006 2638 2643
161. I. Raz, M. Hanefeld, L. Xu, C. Caria, D. Williams-Herman, H. Khatami Sitagliptin Study 023 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus Diabetologia 49 2006 2564 2571
162. J. Rosenstock, R. Brazg, P.J. Andryuk, K. Lu, P. Stein Sitagliptin Study 019 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 28 2006 1556 1568
163. A.R. Chacra, G.H. Tan, A. Apanovitch, S. Ravichandran, J. List, R. Chen CV181-040 Investigators Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial Int J Clin Pract 63 2009 1395 1406
164. E. Allen, P. Hollander, J. Li, and R. Chen Saxagliptin added to a thiazolidinedione improves glycemic control in patients with inadequately controlled type 2 diabetes Diabetologia 51 suppl 1 2008 S342 S343 EASD abstract 859.
165. E. Bosi, R.P. Camisasca, C. Collober, E. Rochotte, and A.J. Garber Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin Diabetes Care 30 2007 890 895
166. A.J. Garber, A. Schweizer, M.A. Baron, E. Rochotte, and S. Dejager Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study Diabetes Obes Metab 9 2007 166 174
167. 1c over 1 year in drug-nave patients with Type 2 diabetes Diabet Med 24 2007 955 961
168. R. Scott, T. Loeys, M.J. Davies, S.S. Engel Sitagliptin Study 801 Group Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes Diabetes Obes Metab 10 2008 959 969
169. M. Hanefeld, G.A. Herman, M. Wu Sitagliptin Study 014 Investigators Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes Curr Med Res Opin 23 2007 1329 1339
170. R.A. DeFronzo, M.N. Hissa, A.J. Garber Saxagliptin 014 Study Group The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone Diabetes Care 32 2009 1649 1655
171. E. Ferrannini, V. Fonseca, and B. Zinman Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy Diabetes Obes Metab 11 2009 157 166
172. A.J. Garber, J.E. Foley, and M.A. Banerji Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea Diabetes Obes Metab 10 2008 1047 1056
173. F.X. Pi-Sunyer, A. Schweizer, D. Mills, and S. Dejager Efficacy and tolerability of vildagliptin monotherapy in drug-nave patients with type 2 diabetes Diabetes Res Clin Pract 76 2007 132 138 (Pubitemid 46240373)
174. G.C. Mistry, A.L. Maes, and K.C. Lasseter Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension J Clin Pharmacol 48 2008 592 598
175. D.M. Riche, H.E. East, and K.D. Riche Impact of sitagliptin on markers of β-cell function: a meta-analysis Am J Med Sci 337 2009 321 328
176. J. Mu, J. Woods, and Y.P. Zhou Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes Diabetes 55 2006 1695 1704
177. C.J. Girman, T.D. Kou, and B. Cai Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes Diabetes Obes Metab 12 2010 766 771
178. R.A. Noel, D.K. Braun, R.E. Patterson, and G.L. Bloomgren Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study Diabetes Care 32 2009 834 838
179. D.D. Dore, J.D. Seeger, and K.A. Chan Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide Curr Med Res Opin 25 2009 1019 1027
180. US Food and Drug Administration FDA Briefing Materials: Liraglutide http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b2-01-FDA.pdf April 2, 2009 Accessed August 24, 2010
181. L.B. Knudsen, L.W. Madsen, and S. Andersen Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 151 2010 1473 1486
182. American Association of Clinical Endocrinologists Recommendations regarding liraglutide March 15, 2010 [modified March 17, 2010] http://www.aace.com/alert/liraglutide03152010.php Accessed August 26, 2010
183. A.V. Matveyenko, S. Dry, and H.I. Cox Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amuloid polypeptide transgenic rat model of type 2 diabetes Diabetes 58 2009 1604 1615
184. US Food and Drug Administration Information for Healthcare Professionalsacute pancreatitis and sitagliptin (marketed as Januvia and Janumet) [09-25-2009] http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm Accessed August 26, 2010
185. B. Gallwitz Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [published correction appears in IDrugs. 2009;12:200] IDrugs 11 2008 906 917
186. D.M. Nathan, J.B. Buse, and M.B. Davidson Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
187. W.T. Cefalu, R.J. Richards, and L.Y. Melendez-Ramirez Redefining treatment success in type 2 diabetes mellitus: comprehensive targeting of core defects Cleve Clin J Med 76 suppl 5 2009 S39 S47
188. R.M. Bergenstal, C. Wysham, L. MacConell DURATION-2 Study Group Efficacy and safety of exenatide once-weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 376 2010 431 439
189. R.E. Pratley, M. Nauck, T. Bailey 1860-LIRA-DPP-4 Study Group Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 375 2010 1447 1456